LRRC32 and cancer: Although physiologic GARP-TGF-β signaling maintains peripheral tolerance, lrrc32 amplification and overactive GARP-TGF-β signaling have been observed across multiple cancers, correlating with an immune-tolerant microenvironment and poor responses to immune checkpoint inhibitors (ICIs) [12, 75, 76].